Table 5

Results of meta-analysis of studies examining GST polymorphisms and breast cancer risk

Gene (variant)GroupNo. of StudiesaNo. of case subjectsNo. of control subjectsSummary odds ratio (95% confidence interval)Test for heterogeneityReferences
GSTM1 (deletion)All women195,9506,6011.05 (0.98, 1.13)0.56 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Premenopausal102,0332,4850.95 (0.84, 1.07)0.28 10 11 12 13 ,16 17 18 ,21 ,23
Postmenopausal112,5212,9631.14 (1.02, 1.27)0.07 10 ,12 13 14 ,16 17 18 ,21 ,23 ,24
GSTT1 (deletion)All women154,8735,2451.11 (1.01, 1.22)0.03 10 11 12 13 ,15 ,17 18 19 20 21 22 23 24 ,26
Premenopausal91,8102,1511.13 (0.98, 1.31)0.05 10 11 12 13 ,17 ,18 ,21 ,23
Postmenopausal92,4732,1601.10 (0.96, 1.27)0.20 10 ,12 ,13 ,17 ,18 ,21 ,23 ,24
GSTP1b ( 105 Val homozygote) All women102,1362,2821.04 (0.87, 1.25)0.009 10 ,12 ,18 ,19 ,21 ,22 ,27 28 29
Premenopausal58491,0161.21 (0.89, 1.65)0.11 10 ,12 ,18 ,21
Postmenopausal69001,1101.01 (0.78, 1.30)0.02 10 ,12 ,18 ,21 ,28
  • a Current case-control study is included in the analysis.

  • b Odds ratio for GSTP1 for homozygous variant are compared to homozygous wild-type as referent.